Investor's Business Daily on MSN
This biotech dealmaker — tied to Merck, Travere — is in a profit-taking zone
Ligand stock landed in a profit-taking zone Thursday on a strong second-quarter report and an earnings guidance hike.
Ligand Pharmaceuticals (NASDAQ:LGND) reported second-quarter 2026 results marked by higher royalty revenue and adjusted ...
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and six months ended June 30, 2026, and provided an operating forecast and business update. Ligand ...
Investor's Business Daily on MSN
Dow Jones futures rise but techs fall as SanDisk, Western Digital, Datadog lead earnings losers
The Dow Jones hit a new high thanks to Nvidia, but Google, SpaceX and AMD weighed on the Nasdaq. Sandisk, Western Digital ...
Travere Therapeutics Inc. company and executive profile by Barron's. View the latest TVTX company infomation and executive bios.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results